On Sept. 22, 2020, Codagenix announced that the Serum Institute of India has begun manufacturing CDX-005, the company’s intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19.

Codagenix collaborated with the Serum Institute of India to develop CDX-005. Preclinical animal studies were successfully completed, and Codagenix expected to initiate a Phase 1 first-in-human clinical trial in the UK by the end of 2020.